Cargando…

Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease

PURPOSE: This article reviews the efficacy and safety of revefenacin, the first once-daily, long-acting muscarinic antagonist, when delivered via a standard jet nebulizer in patients with chronic obstructive pulmonary disease (COPD). SUMMARY: Revefenacin 175 µg is indicated for the maintenance treat...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hvisdas, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083528/ https://www.ncbi.nlm.nih.gov/pubmed/33821890 http://dx.doi.org/10.1093/ajhp/zxab154

Ejemplares similares

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020)

Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues
por: Hegde, Sharath S., et al.
Publicado: (2018)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
por: Ulrik, Charlotte Suppli
Publicado: (2012)

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease
por: Crater, Glenn D., et al.
Publicado: (2022)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

The Role of Revefenacin in Chronic Obstructive Pulmonary Disease
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
por: Lo, Arthur, et al.
Publicado: (2020)

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
por: Pudi, Krishna K., et al.
Publicado: (2017)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
por: Calzetta, Luigino, et al.
Publicado: (2022)

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review
por: Zhang, Jiaxing, et al.
Publicado: (2021)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
por: Donohue, James, et al.
Publicado: (2019)

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
por: Roberts, Melissa H., et al.
Publicado: (2019)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
por: Umeda, Akira, et al.
Publicado: (2023)

Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2018)

The emerging role of nebulization for maintenance treatment of chronic obstructive pulmonary disease at home
por: Talwar, Deepak, et al.
Publicado: (2021)

Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
por: Cazzola, Mario, et al.
Publicado: (2023)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

Correction to: Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2019)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
por: Donohue, James F., et al.
Publicado: (2019)

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
por: Katsumata, Mineo, et al.
Publicado: (2022)

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
por: Busse, William W., et al.
Publicado: (2016)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
por: Hamelmann, Eckard
Publicado: (2018)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dif75cr790pkgj70jav4d3hm0f